Validation of kinki criteria, a modified substaging system, in patients with intermediate stage hepatocellular carcinoma

Digestive Diseases

Volumn 34, Issue 6, 2016, Pages 671-678

  Arizumi, Tadaaki ^a   Ueshima, Kazuomi ^a   Iwanishi, Mina ^a   Minami, Tomohiro ^a   Chishina, Hirokazu ^a   Kono, Masashi ^a   Takita, Masahiro ^a   Kitai, Satoshi ^a   Inoue, Tatsuo ^a   Yada, Norihisa ^a   Hagiwara, Satoru ^a   Minami, Yasunori ^a   Ida, Hiroshi ^a   Sakurai, Toshiharu ^a   Kitano, Masayuki ^a   Nishida, Naoshi ^a   Kudo, Masatoshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Barcelona Clinic Liver Cancer stage B; Hepatocellular carcinoma; Kinki criteria; Transarterial chemoembolization

Indexed keywords

ANTINEOPLASTIC AGENT; SORAFENIB;

ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; HOSPITAL PATIENT; HUMAN; KINKI CRITERIA; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MEDIAN SURVIVAL TIME; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SURVIVAL RATE; SURVIVAL TIME; UNIVERSITY HOSPITAL; VALIDATION PROCESS; CARCINOMA, HEPATOCELLULAR; CLASSIFICATION; COMPARATIVE STUDY; FOLLOW UP; JAPAN; LIVER NEOPLASMS; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; RETROSPECTIVE STUDY;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; JAPAN; LIVER NEOPLASMS; NEOPLASM STAGING; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84992213016     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000448834     Document Type: Article

References (33)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255
2. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014; 63: 844-855
3. Kudo M. Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer 2015; 4: 39-50
4. Liccioni A, Reig M, Bruix J. Treatment of hepatocellular carcinoma. Dig Dis 2014; 32: 554-563
5. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338
6. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022
7. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943
8. Kudo M. Locoregional therapy for hepatocellular carcinoma. Liver Cancer 2015; 4: 163-164
9. Tsurusaki M, Murakami T. Surgical and locoregional therapy of HCC: TACE. Liver Cancer 2015; 4: 165-175
10. Yamakado K, Miyayama S, Hirota S, Mizunuma K, Nakamura K, Inaba Y, Maeda H, Matsuo K, Nishida N, Aramaki T, Anai H, Koura S, Oikawa S, Watanabe K, Yasumoto T, Furuichi K, Yamaguchi M. Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization. Jpn J Radiol 2014; 32: 260-265
11. Zhong JH, Ke Y, Gong WF, Xiang BD, Ma L, Ye XP, Peng T, Xie GS, Li LQ. Hepatic resection associated with good survival for selected patients with intermediate and advancedstage hepatocellular carcinoma. Ann Surg 2014; 260: 329-340
12. Lin CT, Hsu KF, Chen TW, Yu JC, Chan DC, Yu CY, Hsieh TY, Fan HL, Kuo SM, Chung KP, Hsieh CB. Comparing hepatic resection and transarterial chemoembolization for Barcelona clinic liver cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice' World J Surg 2010; 34: 2155-2161
13. Zhong JH, Xiang BD, Gong WF, Ke Y, Mo QG, Ma L, Liu X, Li LQ. Comparison of longterm survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization. PLoS One 2013; 8: e68193
14. Yin L, Li H, Li AJ, Lau WY, Pan ZY, Lai EC, Wu MC, Zhou WP. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: a RCT. J Hepatol 2014; 61: 82-88
15. Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Kanai F, Yoshikawa M, Yokosuka O. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology 2014; 87: 330-341
16. Kudo M, Matsui O, Izumi N, Kadoya M, Okusaka T, Miyayama S, Yamakado K, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology 2014; 87(suppl 1): 22-31
17. Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M. Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ. Oncology 2014; 87(suppl 1): 32-36
18. Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M. Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinoma. Liver Cancer 2015; 4: 253-262
19. Raoul JL, Gilabert M, Piana G. How to define transarterial chemoembolization failure or refractoriness: a European perspective. Liver Cancer 2014; 3: 119-124
20. Obi S, Sato S, Kawai T. Current status of hepatic arterial infusion chemotherapy. Liver Cancer 2015; 4: 188-199
21. Ueshima K, Kudo M, Tanaka M, Kumada T, Chung H, Hagiwara S, Inoue T, Yada N, Kitai S. Phase I/II study of sorafenib in combination with hepatic arterial infusion chemotherapy using low-dose cisplatin and 5-fluorouracil. Liver Cancer 2015; 4: 263-273
22. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43
23. Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, Raoul JL, Sangro B. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012; 32: 348-359
24. Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Ida H, Minami Y, Sakurai T, Kitano M, Nishida N, Kudo M. Validation of a modified substaging system (Kinki criteria) for patients with intermediate-stage hepatocellular carcinoma. Oncology 2015; 89(suppl 2): 47-52
25. Kudo M, Arizumi T, Ueshima K, Sakurai T, Kitano M, Nishida N. Subclassification of BCLC B stage hepatocellular carcinoma and treatment strategies: proposal of modified Bolondi's subclassification (Kinki criteria). Dig Dis 2015; 33: 751-758
26. Miyayama S, Matsui O, Yamashiro M, Ryu Y, Kaito K, Ozaki K, Takeda T, Yoneda N, Notsumata K, Toya D, Tanaka N, Mitsui T. Ultraselective transcatheter arterial chemoembolization with a 2-F tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol 2007; 18: 365-376
27. Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, Miyayama S, Takashima T, Unoura M, Kogayashi K. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993; 188: 79-83
28. Miyayama S, Matsui O, Zen Y, Yamashiro M, Hattori Y, Orito N, Matsui K, Tsuji K, Yoshida M, Sudo Y. Portal blood supply to locally progressed hepatocellular carcinoma after transcatheter arterial chemoembolization: observation on CT during arterial portography. Hepatol Res 2011; 41: 853-866
29. Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 2008; 49: 523-529
30. Zen C, Zen Y, Mitry RR, Corbeil D, Karbanova J, O'Grady J, Karani J, Kane P, Heaton N, Portmann BC, Quaglia A. Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation. Liver Transpl 2011; 17: 943-954
31. Kojiro M, Sugihara S, Kakizoe S, Nakashima O, Kiyomatsu K. Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy. Cancer Chemother Pharmacol 1989; 23(suppl): S4-S8
32. Ishikura H, Sotozaki Y, Adachi H, Sato M, Yoshiki T. Granulomatous arteritis with massive eosinophilic leukocyte infiltration and transient peripheral eosinophilia subsequent to transarterial embolization therapy with a gelatin sponge. Acta Pathol Jpn 1991; 41: 618-622
33. Lin CC, Cheng YT, Chen M WT, Lin SM. The effectiveness of multiple electrode radiofrequency ablation in patients with hepatocellular carcinoma with lesions more than 3 cm in size and Barcelona clinic liver cancer stage A to B2. Liver Cancer 2016; 5: 8-20